Mixed

Dual SGLT1/SGLT2 inhibition with licogliflozin produces statistically significant but modest body weight loss (mean -3.73% to -3.83%) in adults with overweight or obesity, with responder rates (≥5% loss) reaching 45.3% at high doses, though accompanied by dose-dependent gastrointestinal adverse events.

Licogliflozin, a dual SGLT1/SGLT2 inhibitor, leads to modest but statistically significant weight loss (around 3-4% on average) in adults with overweight or obesity over 24 weeks. While about 45% of patients taking the highest doses lose at least 5% of their body weight, the average effect is smaller than other anti-obesity medications. Treatment is associated with gastrointestinal side effects like diarrhea, which are dose-dependent and often improve over time or with dose reduction. Patients should expect a gradual, modest weight loss rather than a dramatic reduction, and must adhere to lifestyle interventions (caloric restriction and exercise) as part of the protocol.